Kai Wang

Kai Wang

Auto-generated profile, based on publicly available information

Kai Wang

Pfizer, Inc., San Diego, CA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2014 in Nature Genetics
Verified
Journal Article
Closed access
KWKai Wang
Kai Wang
SYSiu Tsan Yuen
Siu Tsan Yuen
JXJiangchun Xu
Jiangchun Xu
SLSiu Po Lee
Siu Po Lee
HYHelen H N Yan
Helen H N Yan
SLSum Yee Yee Leung
Sum Yee Yee Leung

30 October 2011 in Nature Genetics
Verified
Journal Article
Closed access
KWKai Wang
Kai Wang
JKJunsuo Kan
Junsuo Kan
SYSiu Tsan Yuen
Siu Tsan Yuen
SSStephanie T Shi
Stephanie T Shi
KCKent Man Chu
Kent Man Chu
SLSum Yee Yee Leung
Sum Yee Yee Leung

20 June 2013 in Genome Research
Verified
Journal Article
Open access
PDF file
ZKZhengyan Kan
Zhengyan Kan
HZHancheng Zheng
Hancheng Zheng
XLXiao Liu
Xiao Liu
SLShuyu Li
Shuyu Li
TBThomas D. Barber
Thomas D. Barber
MMMao Mao
Mao Mao
Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide and has no effective treatment, yet the molecular basis of hepatocarcinogenesis remains largely unknown. Here we report findings from a whole-genome sequencing (WGS) study of 88 matched HCC tumor/normal pairs, 81 of which are Hepatitis B virus (HBV) positive, seeking to identify genetically altered genes and pathways implicated in HBV-associated HCC. We find beta-catenin to be the most frequently mutated oncogene (15.9%) and TP53 the most frequently mutated tumor suppressor (35.2%). The Wnt/beta-catenin and JAK/STAT pathways, altered in 62.5% and 45.5% of cases, respectively, are likely to act as two major oncogenic drivers in HCC. This study also identifies several prevalent and potentially actionable mutations, including activating mutations of Janus kinase 1 (JAK1), in 9.1% of patients and provides a path toward therapeutic intervention of the disease.

8 June 2010 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
CLCeline Lefebvre
Celine Lefebvre
PRPresha Rajbhandari
Presha Rajbhandari
MAMariano J Alvarez
Mariano J Alvarez
PBPradeep Bandaru
Pradeep Bandaru
WLWei Keat Lim
Wei Keat Lim
ACAndrea Califano
Andrea Califano
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

27 June 2006 in Nature Protocols
Verified
Journal Article
Closed access
AMAdam A Margolin
Adam A Margolin
KWKai Wang
Kai Wang
WLWei Keat Lim
Wei Keat Lim
MKManjunath Kustagi
Manjunath Kustagi
INIlya Nemenman
Ilya Nemenman
ACAndrea Califano
Andrea Califano

4 February 2010 in Blood
Verified
Journal Article
Open access
PDF file
KBKatia Basso
Katia Basso
MSMasumichi Saito
Masumichi Saito
PSPavel Sumazin
Pavel Sumazin
AMAdam A. Margolin
Adam A. Margolin
KWKai Wang
Kai Wang
RDRiccardo Dalla-Favera
Riccardo Dalla-Favera
BCL6 is a transcriptional repressor required for mature B-cell germinal center (GC) formation and implicated in lymphomagenesis. BCL6's physiologic function is only partially known because the complete set of its targets in GC B cells has not been identified. To address this issue, we used an integrated biochemical-computational-functional approach to identify BCL6 direct targets in normal GC B cells. This approach includes (1) identification of BCL6-bound promoters by genome-wide chromatin immunoprecipitation, (2) inference of transcriptional relationships by the use of a regulatory network reverse engineering approach (ARACNe), and (3) validation of physiologic relevance of the candidate targets down-regulated in GC B cells. Our approach demonstrated that a large set of promoters (> 4000) is physically bound by BCL6 but that only a fraction of them is repressed in GC B cells. This set of 1207 targets identifies several cellular functions directly controlled by BCL6 during GC development, including activation, survival, DNA-damage response, cell cycle arrest, cytokine signaling, Toll-like receptor signaling, and differentiation. These results define a broad role of BCL6 in preventing centroblasts from responding to signals leading to exit from the GC before they complete the phase of proliferative expansion and of antibody affinity maturaton.